Beruflich Dokumente
Kultur Dokumente
SS Visser, Pulmonology
Internal Medicine
UP
Chronic Obstructive pulmonary
Disease
Blood gas:
PaO2 ± 65 mm Hg 45-60
PaCO2 35-40 50-60
Elastic recoil Normal
AW resistance N-
Diffusion Cap
N-
FEV1
Bronchodilator
response Poor Better but < 12% and 200ml
Spirometric classification of
COPD severity using post-
bronchodilator FeV1
Stage I (Mild): FeV1/FVC <0.7; FeV1 80% of
predicted
Stage II (Moderate): FeV1/FVC <0.7; FeV1 50-
<80% of predicted
Stage III (Severe): FeV1/FVC <0.7; FeV1 30-<50%
Stage IV (Very severe): FeV1/FVC <0.7; FeV1
<30% or <50% but chronic respiratory failure is
present. (GOLD 2007)
Treatment: Goals of
management -1
Recognition of disease (early Diagnosis and staging)
Smoking cessation (secondary prevention) nicotine
replacement and Zyban
Improvement of breathlessness (Rx of airflow obstruction-
bronchodilator drugs)
1.Methylxanthines
2.Short and long-acting B2adrenergic agonists ( incidence of
pneumonia with ICS and LABA combinations)
3.Short and long-acting Anticholinergics- BD of choice in
COPD
Treatment -2
Smoking
Hyperinflation
Airway collapse
Respiratory infection
Bronchospasm
Allergy
Inflammation
Airway Diseases : Asthma
Allergy
Inflammation
Bronchospasm
Hyperinflation
Respiratory infection
AirwayDiseases:Bronchiectasis
Respiratory infection
Hyperinflation
Bronchospasm
Inflammation
Allergy